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To the editor:  
We read with interest the article by Price et al 1 showing a clear association between 
asthma control and a spot measurement of blood eosinophils. The mean 
belcometasone equivalent inhaled corticosteroid (ICS) dose in their cohort was 
219ug/day. It is important to consider the dose response relationship of ICS dose on 
blood eosinophils. There is evidence of a dose response effect of ICS on reduction of 
blood eosinophils and eosinophilic cationic protein (ECP) for beclometasone 
equivalent ICS doses of up to 800ug/day.2-4 In terms of mechanism it appears that 
dose related reduction in blood eosinophils and ECP by ICS is disconnected from 
commensurate adrenal suppression,3,5 suggesting that systemic bioavailability of ICS 
may not be the principal cause of suppressing blood eosinophils.  
The data from Price et al 1 were somewhat conflicting showing that patients on step 
4 therapy with high dose ICS had a 13% increased likelihood of having a blood 
eosinophil count >400 cells /uL, which was not observed for step 3 patients who 
were also taking ≥ 800ug/day beclometasone equivalent ICS dose, while step 2 
patients on low dose ICS were 8% less likely to have a raised count. However we 
appreciate that it might be difficult to dissect out the suppressive effects of ICS on 
eosinophils per se from the ICS dose being a proxy for associated asthma severity.  
Titrating ICS dose over 1 year against mannitol airway hyper-responsiveness,5 results 
in reduced exacerbations, improved symptom control and reduced reliever use, 
accompanied by a 34% fall in ECP. The relative suppression of eosinophils and ECP in 
response to 400ug/day beclometasone equivalent ICS dose is 23% and 17% 
respectively for blood and 76% and 55% for sputum,6 inferring that sputum is more 
3 
 
sensitive, although it is less practical. In this regard it has been shown that titrating 
ICS against sputum eosinophils results in reduced exacerbations and associated 
AHR.7 It would therefore be relevant to know if using serial blood eosinophils to 
adjust the ICS dose might result in reduced exacerbations, especially in patients who 
already have an optimised asthma control questionnaire score <0·758 at the time 
when the eosinophil count is measured. 
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